Business Wire

LEO Pharma Expands Partnering Presence with LEO Science & Tech Hub in Boston

Del

LEO Pharma, a global healthcare company dedicated to helping people achieve healthy skin, today announced the official inauguration of the LEO Science & Tech Hub in Boston by Her Royal Highness, Crown Princess Mary of Denmark. The event, which also includes participation from the Danish Minister for Business and Growth Troels Lund Poulsen, brings together members of the Boston life science community to explore opportunities for partnership and innovation.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160930005376/en/

(Graphic: LEO Science & Tech Hub)

(Graphic: LEO Science & Tech Hub)

The Hub aims to catalyze early-stage collaborations in science and technology in order to advance the treatment of skin diseases and is the first of its kind to focus on dermatology in the Greater Boston area, the world’s leading life science cluster.

“With the establishment of the LEO Science & Tech Hub at the epicenter of this world-leading biotech supercluster, LEO Pharma is poised to foster novel collaborations that can lead to significant advances in science,” says Kim Kjoeller, Executive Vice President, Global Research & Development, LEO Pharma. “By creating alliances with industry and academia here in the region, we hope to change the treatment paradigm in dermatology and improve the quality of life of people with skin diseases.”

The LEO Science & Tech Hub will build early-stage collaborations with academic centers, entrepreneurs and companies in the United States – and support collaborators in validating novel targets in skin diseases and advancing technology towards commercialization. The Hub team has access to full deal-making capabilities and can provide support in terms of seed investments and co-development, including access to LEO Pharma’s global network of dermatology expertise. Collaborators can access LEO Pharma’s preclinical and clinical expertise as well as the digital healthcare expertise of LEO Innovation Lab.

“The LEO Science & Tech Hub wants to join forces with life science innovators in the US to change the treatment paradigm for people with skin diseases and take the first steps towards precision medicine in dermatology,” says Michael Sierra, Vice President, LEO Science & Tech Hub. “By offering our collaborators access to funding and a unique global network of dermatology expertise, we want to act as catalysts for innovation and help bring new science and technology to the next stage.”

The Hub’s team of science experts will engage with partners in three areas: cognitive computer learning, imaging, and biomarkers. For example, the Hub will explore the use of smart phones to help patients monitor their disease and track treatment progress. The Hub will also explore advanced imaging technologies as a valid and reliable alternative to skin biopsies. The overall aim is to enable patients and doctors to monitor, diagnose, and treat skin diseases in a more effective and less invasive way.

The LEO Science & Tech Hub is located in the heart of the Kendall Square innovation district at the CIC in Cambridge, Massachusetts.

“We congratulate LEO Pharma on the opening of the new LEO Science & Tech Hub in Kendall Square,” said Robert K. Coughlin, President & CEO of MassBio. “We know that LEO Pharma’s collaborative spirit will cultivate new partnerships in the Hub that will advance precision medicine in dermatology and ultimately speed the development of innovative treatments for patients around the world.”

“LEO Pharma’s new dermatology-focused LEO Science & Tech Hub is a welcome addition to the many life sciences centers of excellence that are operating and innovating in and around Boston and Cambridge,” said Travis McCready, President & CEO of the Massachusetts Life Sciences Center. “Skin diseases are more common than one might expect - every year one in four Americans consult their primary care physician regarding a skin concern. We look forward to collaborating with LEO Pharma as they put down roots and form partnerships within the world’s leading ecosystem for life sciences innovation and growth.”

“We are excited for LEO Pharma to join Massachusetts’ thriving life sciences ecosystem, bringing the first center focused exclusively on dermatology to the Commonwealth,” said Charlie Baker, Governor of Massachusetts. “This new facility will advance research and the development of new treatments in the field of dermatology, while opening up new opportunities for collaboration between the life sciences communities in Massachusetts and Denmark.”

About LEO Pharma

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide.

For more information, visit www.leo-pharma.com
Subscribe to our YouTube channel: www.youtube.com/leopharmaglobal
Follow us on Twitter: www.twitter.com/leohealthyskin
Visit us at LinkedIn: www.linkedin.com/company/leo-pharma

About LEO Science & Tech Hub

LEO Science & Tech Hub explores cutting-edge science and technology opportunities with relevance to dermatology. By partnering with public and private institutions, the LEO Science & Tech Hub acts as a catalyst that transforms early-stage innovations and technologies into solutions that will improve the quality of life for people with skin diseases. LEO Science & Tech Hub is part of LEO Pharma, a global healthcare company dedicated to helping people achieve healthy skin.
www.leo-scitech.com

Contact information

LEO Pharma
Eva Juul Langlands, +45 4188 3094
Media Relations Manager
Global Communications
eva.langlands@leo-pharma.com
or
LaVoieHealthScience
Vivian Ni, +1 617-374-8800 ext. 109
Assistant Account Executive
vni@lavoiehealthscience.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201720.10.2017 21:00Pressemelding

Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are

More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08Pressemelding

The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable

Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15Pressemelding

Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside

Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03Pressemelding

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f

SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47Pressemelding

SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom